The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal L-cells in response to nutrient ingestion, with a physiological half-life of under two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). GLP-1 binds its cognate G-protein-coupled receptor (GLP-1R) on pancreatic beta-cells, activating adenylyl cyclase via Gs, elevating intracellular cAMP, and enhancing glucose-dependent insulin secretion. Simultaneously, GLP-1 suppresses glucagon secretion from alpha-cells, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite — a multifaceted mechanism that addresses several pathophysiological drivers of type 2 diabetes and obesity.
GLP-1 receptor agonists (GLP-1 RAs) are engineered to resist DPP-4 degradation, with half-lives ranging from hours (exenatide twice daily) to approximately one week (semaglutide once weekly). Cardiovascular outcome trials have demonstrated significant reductions in major adverse cardiovascular events (MACE) with liraglutide, semaglutide, and dulaglutide in patients with established cardiovascular disease or high risk, leading to guideline incorporation as preferred agents in this population. Emerging data also support benefits in non-alcoholic fatty liver disease (NAFLD/NASH) via hepatic GLP-1R signalling and weight-dependent mechanisms.
Tirzepatide represents the first approved dual GIP/GLP-1 receptor agonist, activating both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R. This dual agonism produces additive or synergistic effects on weight reduction and glycaemic control compared to GLP-1 RA monotherapy in head-to-head trials. The class is under active investigation for heart failure with preserved ejection fraction, CKD, and obstructive sleep apnoea, reflecting the breadth of GLP-1R expression across organ systems.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal L-cells in response to nutrient ingestion, with a physiological half-life of under two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4).
GLP-1 binds its cognate G-protein-coupled receptor (GLP-1R) on pancreatic beta-cells, activating adenylyl cyclase via Gs, elevating intracellular cAMP, and enhancing glucose-dependent insulin secretion.
Simultaneously, GLP-1 suppresses glucagon secretion from alpha-cells, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite — a multifaceted mechanism that addresses several pathophysiological drivers of type 2 diabetes and obesity.
GLP-1 receptor agonists (GLP-1 RAs) are engineered to resist DPP-4 degradation, with half-lives ranging from hours (exenatide twice daily) to approximately one week (semaglutide once weekly).
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Cardiology / Cardiovascular Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →